These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10755214

  • 1. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.
    Komorowski J, Jankewicz J, Stepień H.
    Cytobios; 2000; 101(398):151-9. PubMed ID: 10755214
    [Abstract] [Full Text] [Related]

  • 2. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [Abstract] [Full Text] [Related]

  • 3. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
    Linder C, Linder S, Munck-Wikland E, Strander H.
    Anticancer Res; 1998 Dec; 18(3B):2063-8. PubMed ID: 9677468
    [Abstract] [Full Text] [Related]

  • 4. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C.
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [Abstract] [Full Text] [Related]

  • 5. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O'Brien S, Keating MJ, Albitar M.
    Cancer; 2002 Nov 01; 95(9):1923-30. PubMed ID: 12404286
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2001 Nov 01; 12(3):445-52. PubMed ID: 11566625
    [Abstract] [Full Text] [Related]

  • 7. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan 01; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 8. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume.
    Davies MM, Jonas SK, Kaur S, Allen-Mersh TG.
    Br J Cancer; 2000 Mar 01; 82(5):1004-8. PubMed ID: 10737380
    [Abstract] [Full Text] [Related]

  • 9. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug 01; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours.
    Kołomecki K, Stepień H, Narebski JM.
    Cytobios; 2000 Aug 01; 101(396):55-64. PubMed ID: 10697745
    [Abstract] [Full Text] [Related]

  • 11. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY.
    Br J Cancer; 1999 May 01; 80(5-6):892-7. PubMed ID: 10360671
    [Abstract] [Full Text] [Related]

  • 12. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L, Andrýs C, Krejsek J, Belada DZ, Zák P, Siroký O, Malý J.
    Vnitr Lek; 2007 Nov 01; 53(11):1171-6. PubMed ID: 18277626
    [Abstract] [Full Text] [Related]

  • 13. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
    Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY.
    Invest Ophthalmol Vis Sci; 2000 Jul 01; 41(8):2115-9. PubMed ID: 10892852
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.
    Clin Cancer Res; 2000 Dec 01; 6(12):4697-704. PubMed ID: 11156222
    [Abstract] [Full Text] [Related]

  • 15. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
    Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen YF, Teicher BA.
    Cancer Chemother Pharmacol; 2003 Apr 01; 51(4):321-7. PubMed ID: 12721760
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.
    Cancer Res; 2001 Mar 15; 61(6):2533-6. PubMed ID: 11289126
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor in angiosarcoma.
    Fujimoto M, Kiyosawa T, Murata S, Matsuo K, Suzuki H, Sone H, Okuda Y, Nakayama Y, Yaoita H.
    Anticancer Res; 1998 Mar 15; 18(5B):3725-9. PubMed ID: 9854484
    [Abstract] [Full Text] [Related]

  • 18. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
    Shang ZJ, Li JR, Li ZB.
    Int J Oral Maxillofac Surg; 2002 Oct 15; 31(5):495-8. PubMed ID: 12418564
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?
    Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Markert U, Bruch HP, Windhövel U.
    Eur J Surg Oncol; 2001 Feb 15; 27(1):37-42. PubMed ID: 11237490
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor in chronic subdural haematomas.
    Shono T, Inamura T, Morioka T, Matsumoto K, Suzuki SO, Ikezaki K, Iwaki T, Fukui M.
    J Clin Neurosci; 2001 Sep 15; 8(5):411-5. PubMed ID: 11535006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.